

Glenmark receives ANDA approval for Deferasirox Tablets

07 January 2020 | News

It is the generic version of Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation



Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.

According to IQVIA™ sales data for the 12-month period ending November 2019, the Exjade® Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg market² achieved annual sales of approximately \$106.4 million.

Glenmark's current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 43 ANDA's pending approval with the U.S. FDA.